Update COVID-19 Malang
Jajak Pendapat

Apa saja gejala COVID-19?

Batuk
Pilek
Sakit Tenggorok
Sesak/Nyeri dada
Semua

Wa Klinik Respirasi Malang Link Reservasi Klinik Peta lokasi klinik Klinik Respirasi Malang Klinik Respirasi Malang
Berita Kesehatan

Computational modelling prediction and clinical validation of impact of benralizumab


Latifa Chachi, Sarah Diver, Himanshu Kaul, Marlon C. Rebelatto, Anmarie Boutrin, Patricia Nisa, Paul Newbold, Christopher Brightling

European Respiratory Journal 2019 54: 1900930; DOI: 10.1183/13993003.00930-2019

Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma

Extract

Asthma is a heterogeneous condition characterised by chronic inflammation and airway remodelling. T2-mediated airway inflammation, characterised by interleukin (IL)-4, IL-5 and IL-13, has been the recent focus of pharmacotherapy, with a host of targeted biologic agents now available to clinicians [1]. The anti-IL-5 receptor agent, benralizumab, causes depletion of eosinophils and basophils via antibody-dependent cell-mediated cytotoxicity in blood; however, the mechanism of action in the tissue is uncertain. Benralizumab has reduced exacerbations and improved lung function in clinical trials.

Footnotes

  • This study is a post-analysis from a previous clinical trial (NCT00659659).

  • Conflict of interest: L. Chachi has nothing to disclose.

  • Conflict of interest: S. Diver has nothing to disclose.

  • Conflict of interest: H. Kaul reports grants from AirPROM, during the conduct of the study.

  • Conflict of interest: M.C. Rebelatto is an employee of and owns shares in AstraZeneca.

  • Conflict of interest: A. Boutrin is an employee of and holds stock options in AstraZeneca.

  • Conflict of interest: P. Nisa has nothing to disclose.

  • Conflict of interest: P. Newbold is an employee of and owns shares in AstraZeneca.

  • Conflict of interest: C. Brightling reports grants and personal fees for consultancy from GlaxoSmithKline, AstraZeneca/Medimmune, Novartis, Chiesi, Roche/Genentech and Boehringer Inglheim, personal fees for consultancy from Vectura, Theravance, PreP, Gilead, Sanofi/Regeneron, Teva, Gossamer and 4DPharma, grants from Pfizer and Mologic, outside the submitted work.

  • Received May 9, 2019.
  • Accepted July 25, 2019.
  • Copyright ©ERS 2019

sumber : https://erj.ersjournals.com/content/54/5/1900930

 
 

PRAKTEK Alamat 1:
RS Panti Waluya /RKZ Sawahan, Lt II-N
, Dr Koentjahja, SpP
Nusakambangan 56, Malang 65117
08113777488 / 362017 ext. 88.23
Pukul 17.30 - selesai, kec. Sabtu / Libur

Alamat 2:
RS Lavalette
, Dr Koentjahja, SpP
WR Supratman 10, Malang 65111
08133175788
Selasa & Kamis, Pukul 16.45 - 17.30

    
RUMAHWilis Indah A-6, Malang 65115
0341-568711


Peta Lokasi